Monopost

Latanoprost.

The active substance is latanoprost.
1 ml eye drops solution contains 50 micrograms of latanoprost.
Excipients/Inactive Ingredients: The other ingredients are: macrogolglycerol hydroxystearate 40, sorbitol, carbomer 974P, macrogol 4000, disodium edetate, sodium hydroxide (for pH-adjustment), water for injections.

MONOPOST belongs to a group of medicines known as prostaglandins. It lowers the pressure within the eye by increasing the natural outflow of fluid from inside the eye into the bloodstream.

MONOPOST is used to treat conditions known as open angle glaucoma and ocular hypertension. Both of these conditions are linked with an increase in the pressure within the eye, eventually affecting the eye sight.

Usual dose: Always use MONOPOST exactly as the doctor has instructed. Check with the doctor or pharmacist if not sure.
The usual dose for adults (including the elderly) is one drop once a day on the affected eye(s). The best time to do this is in the evening.
Do not use MONOPOST more than once a day, because the effectiveness of the treatment can be reduced if MONOPOST is administered more often.
Always use MONOPOST exactly as described previously or as the doctor has instructed, until the doctor tells to stop the treatment. Check with the doctor, or pharmacist or nurse if not sure.
Contact lens wearers: If contact lenses are used, they should be removed before using MONOPOST. After using MONOPOST, wait for 15 minutes before putting the contact lenses back in.
If the patient uses MONOPOST with other eye drops: Wait at least 5 minutes between using MONOPOST and using other eye drops.
If the patient forgets to use MONOPOST: Carry on with the usual dosage at the usual time. Do not take a double dose to make up for a forgotten dose. If unsure about anything, talk to the doctor or pharmacist.
If the patient stops using MONOPOST: Speak to the doctor if the patient wants to stop using of MONOPOST.
For any further questions on the use of this medicine, ask the doctor, or pharmacist or nurse.

If too many drops are administered, some minor irritation in the eye may be experienced, and the eyes may water and turn red.
This should pass, but if the patient is worried, contact the doctor for advice.
Contact the doctor as soon as possible if the patient has swallowed MONOPOST accidentally.

Do not use MONOPOST: If the patient is allergic (hypersensitive) to latanoprost or any other ingredients of this medicine (listed in Description).

Talk to the doctor, or pharmacist or nurse before using MONOPOST if any of the following apply: If the patient is about to have or has had eye surgery (including cataract surgery).
If the patient suffers from eye problems (such as eye pain, irritation or inflammation, blurred vision).
If the patient suffers from dry eyes.
If the patient has severe asthma or an asthma that is not well controlled.
If the patient wears contact lenses, MONOPOST can still be used, but must follow instructions for contact lens wearers in Dosage & Administration.
If the patient has suffered or is currently suffering from a viral infection of the eye caused by the herpes simplex virus (HSV).
Important information about some of the ingredients of MONOPOST: MONOPOST contains macrogolglycerol hydroxystearate (derived from castor oil) which may cause skin reactions.
Driving and using machines: When using MONOPOST, the patient might have blurred vision, for a short time. If this happens, do not drive or use any tools or machines until the vision becomes clear again.
Use in Children: MONOPOST has not been investigated in children (below 18 years).

Do not use MONOPOST while pregnant or breast-feeding.
If the patient is pregnant or breast-feeding, thinks she may be pregnant, or is planning to have a baby, ask the doctor or pharmacist for advice before using this medicine.

Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following are known side effects of using MONOPOST: Very common: may affect more than 1 in 10 people: A gradual change in the eye colour by increasing the amount of brown pigment in the coloured part of the eye known as the iris.
This change is more likely visible in patients with mixed-coloured eyes (blue-brown, grey-brown, yellow-brown or green-brown), than in single-coloured eye patients (blue, grey, green or brown eyes).
Any changes in the eye colour may take years to develop although it is normally seen within 8 months of treatment.
The colour change may be permanent and may be more noticeable if MONOPOST is used in one eye only.
There appears to be no problems associated with the change in eye colour.
The eye colour change does not continue after MONOPOST treatment is stopped.
Redness of the eye.
Eye irritation (a feeling of burning, grittiness, itching, stinging or the sensation of a foreign body in the eye).
A gradual change in the eyelashes of the treated eye and the fine hairs around the treated eye, seen mostly in people of Japanese origin. These changes involve an increase of the colour (darkening), length, thickness and number of the eye lashes.
Common: may affect up to 1 in 10 people: Irritation or disruption to the surface of the eye, eyelid inflammation (blepharitis), eye pain and light sensitivity (photophobia).
Uncommon: may affect up to 1 in 100 people: Eyelid swelling, dryness of the eye, inflammation or irritation of the surface of the eye (keratitis), blurred vision and conjunctivitis; Skin rash.
Rare: may affect up to 1 in 1,000 people: Inflammation of the iris, the coloured part of the eye (iritis/uveitis), swelling of the retina (macular oedema), symptoms of swelling or scratching/damage to the surface of the eye, swelling around the eye (periorbital oedema), misdirected eyelashes or an extra row of eyelashes.
Skin reactions on the eyelids, darkening of the skin of the eyelids.
Asthma, worsening of asthma and shortness of breath (dyspnoea).
Very rare: may affect up to 1 in 10,000 people: Worsening of angina in patients who also have heart disease; Chest pain; Sunken eye appearance (eye sulcus deepening).
Patients have also reported the following side-effects: fluid filled area within the coloured part of the eye (iris cyst), headache, dizziness, awareness of the heart rhythm (palpitations), muscle pain, joint pain and developing a viral infection of the eye caused by the herpes simplex virus (HSV).
Reporting of side effects: If the patient gets any side effects, talk to the doctor, or pharmacist or nurse. This includes any possible side effects not previously listed.
Reporting side effects can help provide more information on the safety of this medicine.

MONOPOST may interact with other medicines. Tell the doctor or pharmacist if the patient is using, has recently used, or might use any other medicines.

Instructions for use: The solution from one individual single dose container of MONOPOST is to be used immediately after opening for administration to the affected eye(s). Since sterility cannot be maintained after the individual single dose container is opened, a new container must be opened prior to each use and must be discarded immediately after administration.
Do not throw away any medicines via wastewater or household waste. Ask the pharmacist how to discard medicines which are no longer used. These measures will help protect the environment.

Store below 25°C.
After first opening the sachet: use the single-dose containers within 7 days.
After first opening of the single-dose container, use immediately and discard the single-dose container after use.

Please follow these instructions to use the drops: 1. Wash your hands and sit or stand comfortably.
2. Use your finger to gently pull down the lower eyelid of your affected eye.
3. Place the tip of the single-dose container close to, but not touching your eye.
4. Squeeze the single-dose container gently so that only one drop goes into your eye, then release the lower eyelid.
5. Press a finger against the corner of the affected eye by the nose. Hold for 1 minute whilst keeping the eye closed.
6. Repeat in your other eye if your doctor has told you to do this.
7. Discard the single-dose container after use. Do not keep it to use it again.

Antiglaucoma Preparations

S01EE01 - latanoprost ; Belongs to the class of prostaglandin analogues. Used in the treatment of glaucoma.

P₁S₁S₃